Form 4: Semler Scientific CEO Granted 15,000 Stock Options

Semler Scientific's CEO, Douglas Murphy-Chutorian, was granted 15,000 stock options exercisable at $17.78 per share.

Summary

• Douglas Murphy-Chutorian, CEO, interim CFO, and Director of Semler Scientific, Inc. (SMLR), acquired 15,000 stock options.
• The options have an exercise price of $17.78 per share.
• The transaction date for the option grant was January 2, 2026.
• The options become exercisable on January 2, 2026, and expire on January 2, 2036.
• The acquisition was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant) which is generally viewed as neutral to slightly positive due to management alignment, but does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The grant of stock options to the CEO aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The transaction was executed under a Rule 10b5-1(c) plan, which demonstrates a pre-planned and transparent approach to insider trading.

Related Party Transactions

• The grant of 15,000 stock options to Douglas Murphy-Chutorian, the CEO, interim CFO, and Director, constitutes a related party transaction as it involves compensation to an executive officer and director.

Stakeholder Impact

• Shareholders: The option grant aims to align the CEO's financial interests with long-term shareholder value creation.
• Management: Provides a significant incentive for the CEO to drive company performance and increase stock price.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) which, while positive for management alignment, does not provide new fundamental information to warrant a change in investment recommendation. It's an expected part of a compensation structure.

Keywords

Semler Scientific, SMLR, Stock Option, Insider Transaction, CEO Compensation, Form 4, Equity Grant, Douglas Murphy-Chutorian